Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells

被引：0

作者：

C Preisinger

J P Schwarz

O B Bleijerveld

E Corradini

P J Müller

K I Anderson

W Kolch

A Scholten

A J R Heck

机构：

[1] Biomolecular Mass Spectrometry and Proteomics Group,Department of Biochemistry

[2] Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences,undefined

[3] Utrecht University,undefined

[4] Netherlands Proteomics Centre,undefined

[5] The Beatson Institute for Cancer Research,undefined

[6] Garscube Estate,undefined

[7] RWTH Aachen University,undefined

[8] Systems Biology Ireland,undefined

[9] University College Dublin,undefined

[10] Belfield,undefined

[11] Centre for Biomedical Genetics,undefined

[12] 7Current address: Proteomics Facility,undefined

[13] Interdisciplinary Centre for Clinical Research (IZKF) Aachen,undefined

[14] RWTH Aachen University,undefined

[15] Aachen,undefined

[16] Germany.,undefined

来源：

Leukemia | 2013年 / 27卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：743 / 746

页数：3

共 50 条

[31] Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia
Carella, Angelo Michele
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (03) : 249 - 251
[32] BCR- ABL KINASE MUTATIONS TO IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA
Thungappa, S. Chiradoni
Singh, T.
Rashmi, N. R.
Lokanatha, D.
Rajshekar, H.
Lakshmaiah, K. C.
Babu, K. G.
Suresh, T. M.
ANNALS OF ONCOLOGY, 2010, 21 : 357 - 357
[33] Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia
Manley, R
Cochrane, J
McDonald, M
Rigby, S
Moore, A
Kirk, A
Clarke, S
Crossen, PE
Morris, CM
Patton, WN
LEUKEMIA, 1999, 13 (01) : 126 - 129
[34] Dendritic cells for vaccination in BCR/ABL-positive chronic myeloid leukemia.
Westermann, J
Kopp, J
Körner, I
Döhner, C
Döhner, H
Mohm, O
Ehninger, G
Richter, G
Dörken, B
Pezzutto, A
BLOOD, 2000, 96 (11) : 144A - 144A
[35] Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors
Radujkovic, Aleksandar
Topaly, Julian
Fruehauf, Stefan
Zeller, W. Jens
ANTICANCER RESEARCH, 2006, 26 (3A) : 2169 - 2177
[36] Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
Xiaoying Lan
Chong Zhao
Xin Chen
Peiquan Zhang
Dan Zang
Jinjie Wu
Jinghong Chen
Huidan Long
Li Yang
Hongbiao Huang
Bing Z. Carter
Xuejun Wang
Xianping Shi
Jinbao Liu
Journal of Hematology & Oncology, 9
[37] Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
Lan, Xiaoying
Zhao, Chong
Chen, Xin
Zhang, Peiquan
Zang, Dan
Wu, Jinjie
Chen, Jinghong
Long, Huidan
Yang, Li
Huang, Hongbiao
Carter, Bing Z.
Wang, Xuejun
Shi, Xianping
Liu, Jinbao
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
[38] BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features
Nina Rosa Neuendorff
Thomas Burmeister
Bernd Dörken
Jörg Westermann
Annals of Hematology, 2016, 95 : 1211 - 1221
[39] Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia
R Manley
J Cochrane
M McDonald
S Rigby
A Moore
A Kirk
S Clarke
PE Crossen
CM Morris
WN Patton
Leukemia, 1999, 13 : 126 - 129
[40] c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia
Prinzhorn W.
Stehle M.
Kleiner H.
Ruppenthal S.
Müller M.C.
Hofmann W.-K.
Fabarius A.
Seifarth W.
Biomarker Research, 4 (1)

← 1 2 3 4 5 →